Testing HS-10587 for Advanced Solid Tumors with MTAP Deletion
Part of Cancer clinical trials.
This early-stage trial tests a new drug called HS-10587 in patients whose advanced cancers have a specific genetic feature (MTAP deletion) and have not responded to standard treatments. The drug may help slow or stop cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be advanced or have spread, confirmed by biopsy, and you've tried at least one standard treatment that didn't work or you couldn't tolerate it
- Your tumor must have a specific genetic deletion called MTAP deletion (confirmed by testing your tumor tissue)
- You must be in good enough health to tolerate the study (ECOG performance status 0 or 1, meaning you can do most daily activities)
- You must have at least one measurable tumor that can be tracked on scans
- Expected life expectancy of at least 12 weeks
- If you can have children, you must agree to use birth control and not breastfeed during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called PEP08 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). It might be an option if standard treatments no longer work or cause too many side effects.
This trial tests a new experimental drug (HSK41959) for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and effective for tumors that no longer respond to standard treatments.
This trial tests a new tablet, DC50292A, for people whose cancer has an MTAP gene deletion. It is for patients whose cancer has spread or returned and who have not had success with other treatments.
This early-stage trial tests a new drug called CS08399 in people with advanced or hard-to-treat cancers (solid tumors or lymphoma) that have a specific genetic change called MTAP deletion. The drug may help slow or stop cancer growth in people whose cancers no longer respond to standard treatments.
This trial tests a new drug called BAY 3713372 in people with solid tumors that have a specific genetic change called MTAP deletion. The drug targets a process inside cells that may help stop tumor growth.
This trial tests an experimental drug called BMS-986504, given alone or with other drugs, for people with advanced solid tumors that have a specific genetic change called a homozygous MTAP deletion. It may be an option if standard treatments are no longer working or aren't available.
Hear when a new MTAP Deletion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.